Impacto del antecedente de aborto en la respuesta renal al tratamiento en pacientes con Nefritis Lúpica y Síndrome Antifosfolípido en un centro de referencia del Caribe Colombiano (2021–2025)
| datacite.rights | http://purl.org/coar/access_right/c_f1cf | |
| dc.contributor.advisor | Aroca Martínez, Gustavo | |
| dc.contributor.advisor | González Torres, Henry Joseth | |
| dc.contributor.author | Padilla Lince, Daniela Vanessa | |
| dc.contributor.author | Antolínez Galván, Fabio Armando | |
| dc.date.accessioned | 2026-01-30T20:35:48Z | |
| dc.date.available | 2026-01-30T20:35:48Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Introducción: La nefritis lúpica es una de las manifestaciones más severas del lupus y un determinante clave de morbimortalidad renal. La presencia concomitante de síndrome antifosfolípido y antecedentes obstétricos adversos, como el aborto espontáneo, puede indicar un fenotipo inmunotrombótico de alto riesgo con menor respuesta renal al tratamiento. Objetivo: Evaluar el impacto del antecedente de aborto en la respuesta renal al tratamiento y en los desenlaces clínico-patológicos de pacientes con nefritis lúpica, considerando el posible rol modulador del síndrome antifosfolípido (SAF). Metodología: Se realizó una cohorte retrospectiva (2021–2025) en un centro del Caribe colombiano con pacientes ≥18 años con NL confirmada. Se compararon respuesta renal, tiempo a remisión y recaídas según antecedente de aborto, mediante análisis descriptivo, bivariado, multivariado y de supervivencia. | spa |
| dc.description.abstract | Background: Lupus nephritis is one of the most severe manifestations of systemic lupus erythematosus and a key determinant of renal morbidity and mortality. The concomitant presence of antiphospholipid syndrome (APS) and adverse obstetric outcomes, such as spontaneous abortion, may indicate a high-risk immunothrombotic phenotype with poorer renal response to treatment. Objective: To evaluate the impact of a history of miscarriage on the renal response to treatment and on the clinical-pathological outcomes of patients with lupus nephritis, considering the potential modulatory role of antiphospholipid syndrome (APS). Methods: A retrospective cohort (2021–2025) was conducted in a reference center in the Colombian Caribbean, including patients ≥18 years with biopsy-confirmed lupus nephritis. Renal response, time to remission, and relapse rates were compared according to abortion history using descriptive, bivariate, multivariate, and survival analyses | eng |
| dc.format.mimetype | ||
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/17316 | |
| dc.language.iso | spa | |
| dc.publisher | Ediciones Universidad Simón Bolívar | spa |
| dc.publisher | Facultad de ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/embargoedAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Nefritis lúpica | spa |
| dc.subject | Síndrome antifosfolípido | spa |
| dc.subject | Aborto espontáneo | spa |
| dc.subject | Respuesta renal | spa |
| dc.subject | Microangiopatía trombótica | spa |
| dc.subject | Lupus eritematoso sistémico | spa |
| dc.subject.keywords | Lupus nephritis | eng |
| dc.subject.keywords | Antiphospholipid syndrome | eng |
| dc.subject.keywords | Spontaneous abortion | eng |
| dc.subject.keywords | Renal response | eng |
| dc.subject.keywords | Thrombotic microangiopathy | eng |
| dc.subject.keywords | Systemic lupus erythematosus | eng |
| dc.title | Impacto del antecedente de aborto en la respuesta renal al tratamiento en pacientes con Nefritis Lúpica y Síndrome Antifosfolípido en un centro de referencia del Caribe Colombiano (2021–2025) | spa |
| dc.type.driver | info:eu-repo/semantics/other | |
| dc.type.spa | Otros | |
| dcterms.references | Hoxha A, Lovisotto M, Perin N, Nalesso F, Del Prete D, Simioni P. Antiphospholipid antibodies nephropathy is associated with an increased risk of kidney failure: a systematic literature review and meta-analysis. Clin Kidney J 2024;17:sfae302. https://doi.org/10.1093/ckj/sfae302. | eng |
| dcterms.references | Domingues V, Chock EY, Dufrost V, Risse J, Seshan S V, Barbhaiya M, et al. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev 2022;21:103158. https://doi.org/10.1016/j.autrev.2022.103158. | eng |
| dcterms.references | Renaudineau Y, Brooks W, Belliere J. Lupus Nephritis Risk Factors and Biomarkers: An Update. Int J Mol Sci 2023;24. https://doi.org/10.3390/ijms241914526. | eng |
| dcterms.references | Park DJ, Joo Y Bin, Bang S-Y, Lee J, Lee H-S, Bae S-C. Predictive Factors for Renal Response in Lupus Nephritis: A Single-center Prospective Cohort Study. J Rheum Dis 2022;29:223–31. https://doi.org/10.4078/jrd.22.0006. | eng |
| dcterms.references | Rodríguez-Almaraz E, Gutiérrez-Solís E, Rabadán E, Rodríguez P, Carmona L, Morales E, et al. Something new about prognostic factors for lupus nephritis? A systematic review. Lupus 2021;30:2256–67. https://doi.org/10.1177/09612033211061475. | eng |
| dcterms.references | Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open 2020;6. https://doi.org/10.1136/rmdopen-2020-001263. | eng |
| dcterms.references | Parikh S V., Almaani S, Brodsky S, Rovin BH. Update on Lupus Nephritis: Core Curriculum 2020. Am J Kidney Dis 2020;76:265–81. https://doi.org/10.1053/j.ajkd.2019.10.017. | eng |
| dcterms.references | Simard JF, Liu EF, Chakravarty E, Rector A, Cantu M, Kuo DZ, et al. Pregnancy Outcomes in a Diverse US Lupus Cohort. Arthritis Care Res (Hoboken) 2024;76:526–30. https://doi.org/10.1002/acr.25279. | eng |
| dcterms.references | Mineo C, Shaul PW, Bermas BL. The pathogenesis of obstetric APS: a 2023 update. Clin Immunol 2023;255:109745. https://doi.org/10.1016/j.clim.2023.109745. | eng |
| dcterms.references | Sun C, Li X, Li X. Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review. Arch Gynecol Obstet 2025;312:1025–36. https://doi.org/10.1007/s00404-025-08106-3. | eng |
| dcterms.references | Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. Semin Arthritis Rheum 2010;39:257–68. https://doi.org/10.1016/j.semarthrit.2008.10.007. | eng |
| dcterms.references | Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus 2015;24:536–45. https://doi.org/10.1177/0961203314567753. | eng |
| dcterms.references | Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024;105:S1–69. https://doi.org/10.1016/j.kint.2023.09.002. | eng |
| dcterms.references | Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae S-C, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 2024;83:15–29. https://doi.org/10.1136/ard-2023-224762. | eng |
| dcterms.references | Arreola-Diaz R, Majluf-Cruz A, Sanchez-Torres LE, Hernandez-Juarez J. The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System. Clin Appl Thromb Hemost 2022;28:10760296221088576. https://doi.org/10.1177/10760296221088576. | eng |
| dcterms.references | Vélez-Verbel M, Aroca-Martínez G, Vélez-Verbel D, Domínguez-Vargas A, Vallejo-Patiño M, Sarmiento-Gutierrez J, et al. Clinical and Immunological Factors Associated with the Progression of Lupus Nephritis in a Population from the Colombian Caribbean. Biomedicines 2024;12:2047. https://doi.org/10.3390/biomedicines12092047. | eng |
| dcterms.references | Domínguez-Vargas A, González-Torres H, Martínez-Bayona Á, SanguinoJaramillo M, Vélez-Verbel M, Cadena-Bonfanti A, et al. Treatment adherence and quality of life in colombian patients with lupus nephritis. Lupus 2024;33:1317–27. https://doi.org/10.1177/09612033241280548. | eng |
| dcterms.references | Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Prim 2016;2:1–21. https://doi.org/10.1038/nrdp.2016.39. | eng |
| dcterms.references | Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 2020;21:605–14. https://doi.org/10.1038/s41590-020-0677-6. | eng |
| dcterms.references | Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol 2017;12:825–35. https://doi.org/10.2215/CJN.05780616. | eng |
| dcterms.references | Lech M, Anders H-J. The pathogenesis of lupus nephritis. J Am Soc Nephrol 2013;24:1357–66. https://doi.org/10.1681/ASN.2013010026. | eng |
| dcterms.references | de Zubiria Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012;2012:849684. https://doi.org/10.1155/2012/849684. | eng |
| dcterms.references | Jackson SW, Alpers CE. Lupus nephritis transcriptomics across space and time. Kidney Int 2022;102:694–6. https://doi.org/10.1016/j.kint.2022.06.028. | eng |
| dcterms.references | Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int 2018;93:789–96. https://doi.org/10.1016/j.kint.2017.11.023. | eng |
| dcterms.references | Choi S-E, Fogo AB, Lim BJ. Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance. Kidney Res Clin Pract 2023;42:166–73. https://doi.org/10.23876/j.krcp.22.083. | eng |
| dcterms.references | Bawazir Y. Clinicopathological correlation of patients with lupus nephritis: Data from a tertiary center in Saudi Arabia. Medicine (Baltimore) 2024;103:e37821. https://doi.org/10.1097/MD.0000000000037821. | eng |
| dcterms.references | Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens 2005;14:1–8. https://doi.org/10.1097/00041552-200501000-00002. | eng |
| dcterms.references | Gibson KL, Gipson DS, Massengill SA, Dooley MA, Primack WA, Ferris MA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol 2009;4:1962–7. https://doi.org/10.2215/CJN.00490109. | eng |
| dcterms.references | Basuli D, Roy S, Ray AS, Kavcar AS, Giorgino FP, Lawson C. Biologic therapies for lupus nephritis: a systematic review of efficacy, safety, and costeffectiveness 2025. https://doi.org/10.21203/rs.3.rs-7608456/v1. | eng |
| dcterms.references | Robles-Marhuenda A, Cobo-Ibáñez T, Noblejas-Mozo A, Muñóz-Fernández S. Biological sequential therapy with rituximab-belimumab in patients with recurrent lupus nephritis. Reumatol Clínica (English Ed 2023;19:290–1. https://doi.org/10.1016/j.reumae.2022.03.001. | eng |
| dcterms.references | Rojas-Rivera JE, García-Carro C, Ávila AI, Espino M, Espinosa M, FernándezJuárez G, et al. Diagnosis and treatment of lupus nephritis: a summary of the Consensus Document of the Spanish Group for the Study of Glomerular Diseases (GLOSEN). Clin Kidney J 2023;16:1384–402. https://doi.org/10.1093/ckj/sfad055. | eng |
| dcterms.references | Martinez GA, Dominguez-Vargas A, Torres HJG, Musso CG, Sanguino MG, Velez MD, et al. Clinical Characterization and Outcomes of Lupus Nephritis in the Colombian Caribbean: Data from the Lupus Nephritis Register (RENELUP). J Am Soc Nephrol 2023;34:282–3. https://doi.org/10.1681/ASN.20233411S1282d. | eng |
| dcterms.references | Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295– 306. https://doi.org/10.1111/j.1538-7836.2006.01753.x. | eng |
| dcterms.references | Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo M-C, et al. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria. Arthritis Rheumatol (Hoboken, NJ) 2023;75:1687–702. https://doi.org/10.1002/art.42624. | eng |
| dcterms.references | Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011;7:330–9. https://doi.org/10.1038/nrrheum.2011.52. | eng |
| dcterms.references | Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 2010;19:370–8. https://doi.org/10.1177/0961203309360810. | eng |
| dcterms.references | Velásquez M, Rojas M, Abrahams VM, Escudero C, Cadavid ÁP. Mechanisms of Endothelial Dysfunction in Antiphospholipid Syndrome: Association With Clinical Manifestations. Front Physiol 2018;9:1840. https://doi.org/10.3389/fphys.2018.01840. | eng |
| dcterms.references | Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol 2016;3:75–84. https://doi.org/10.5152/eurjrheum.2015.0085. | eng |
| dcterms.references | Parodis I, Arnaud L, Gerhardsson J, Zickert A, Sundelin B, Malmström V, et al. Antiphospholipid Antibodies in Lupus Nephritis. PLoS One 2016;11:e0158076. https://doi.org/10.1371/journal.pone.0158076. | eng |
| dcterms.references | Turrent-Carriles A, Herrera-Félix JP, Amigo M-C. Renal Involvement in Antiphospholipid Syndrome. Front Immunol 2018;9:1008. https://doi.org/10.3389/fimmu.2018.01008. | eng |
| dcterms.references | Sakamaki Y, Konishi K, Hashiguchi A, Tomita S, Kubota E, Itoh H, et al. [Renal thrombotic microangiopathy and antiphospholipid syndrome nephropathy in a patient with lupus nephritis]. Nihon Jinzo Gakkai Shi 2016;58:45–54. | eng |
| dcterms.references | Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol 2018;9:1181. https://doi.org/10.3389/fimmu.2018.01181. | eng |
| dcterms.references | Massicotte-Azarniouch D, Kotzen E, Todd S, Hu Y, Hogan SL, Jain K. Kidney thrombotic microangiopathy in lupus nephritis: Impact on treatment and prognosis. Lupus 2022;31:1175–85. https://doi.org/10.1177/09612033221106301. | eng |
| dcterms.references | Zhang P, Yang X, Fu M-Z, Gao C-L, Fang X, Xia Z-K. Risk Factors and Clinical Outcomes of Renal Thrombotic Microangiopathy in Children with Lupus Nephritis in Terms of Pathological and Clinical Features. Nephron 2024;148:609–17. https://doi.org/10.1159/000538240. | eng |
| dcterms.references | Zhang Q, Ren Z, Li J, Zou Z. Anticardiolipin Antibody Plays a More Important Role Than Anti-β2-Glycoprotein I Antibody in Activating Complement in Patients with Lupus Nephritis. Int J Gen Med 2024;Volume 17:517–23. https://doi.org/10.2147/IJGM.S449509. | eng |
| dcterms.references | Park MH, Caselman N, Ulmer S, Weitz IC. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2018;2:2090–4. https://doi.org/10.1182/bloodadvances.2018019596. | eng |
| dcterms.references | Hoxha A, Del Prete D, Condonato I, Martino FK, Lovisotto M, Nalesso F, et al. Perspective on Renal Involvement in Antiphospholipid Syndrome: Implications for Diagnosis, Pathogenesis, and Treatment. J Clin Med 2025;14:3326. https://doi.org/10.3390/jcm14103326. | eng |
| dcterms.references | Talari K, Anandh U, Patrick A. Lupus Nephritis with Coexistent Antiphospholipid Antibodies Associated Nephropathy: A Case Report and Literature Review. Indian J Nephrol 2018;28:164–6. https://doi.org/10.4103/ijn.IJN_204_16. | eng |
| dcterms.references | Sciascia S, Yazdany J, Dall’Era M, Fenoglio R, Radin M, Aggarwal I, et al. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Ann Rheum Dis 2019;78:1004– 6. https://doi.org/10.1136/annrheumdis-2018-214559. | eng |
| dcterms.references | Rosta K, Heinzl F, Kuczwara V, Schindler S, Falcone V, Catic A, et al. Pregnancy outcomes in patients with systemic lupus erythematosus compared to a high-risk tertiary cohort and to standard population from the Austrian birth registry. Acta Obstet Gynecol Scand 2024;103:1820–8. https://doi.org/10.1111/aogs.14880. | eng |
| dcterms.references | Wind M, Fierro JJ, Bloemenkamp KWM, de Leeuw K, Lely AT, Limper M, et al. Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis. Lancet Rheumatol 2024;6:e667–83. https://doi.org/10.1016/S2665-9913(24)00160-7. | eng |
| dcterms.references | Out HJ, Bruinse HW, Christiaens GC, van Vliet M, de Groot PG, Nieuwenhuis HK, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992;167:26–32. https://doi.org/10.1016/s0002-9378(11)91619-6. | eng |
| dcterms.references | Alarcón GS. Multiethnic lupus cohorts: What have they taught us? Reumatol Clínica 2011;7:3–6. https://doi.org/10.1016/j.reuma.2010.11.001. | eng |
| dcterms.references | De Carolis S, Botta A, Santucci S, Garofalo S, Martino C, Perrelli A, et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol 2010;38:116–24. https://doi.org/10.1007/s12016-009- 8144-z. | eng |
| dcterms.references | Di Simone N, Raschi E, Testoni C, Castellani R, D’Asta M, Shi T, et al. Pathogenic role of anti-β2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of β2-glycoprotein I binding to trophoblast cells and functional effects of anti-β2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005;64:462–7. https://doi.org/10.1136/ard.2004.021444. | eng |
| dcterms.references | Shamonki JM, Salmon JE, Hyjek E, Baergen RN. Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies. Am J Obstet Gynecol 2007;196:167.e1-5. https://doi.org/10.1016/j.ajog.2006.10.879 | eng |
| dcterms.references | Bravo-Barrera J, Kourilovitch M, Galarza-Maldonado C. Neutrophil Extracellular Traps, Antiphospholipid Antibodies and Treatment. Antibodies (Basel, Switzerland) 2017;6. https://doi.org/10.3390/antib6010004. | eng |
| dcterms.references | Viall CA, Chamley LW. Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature. Autoimmun Rev 2015;14:446–71. https://doi.org/10.1016/j.autrev.2015.01.008. | eng |
| dcterms.references | Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost 2021;19:607–16. https://doi.org/10.1111/jth.15082. | eng |
| dcterms.references | Negatu SG, Jurado KA. Targeting pathogenic interferon-stimulated gene RSAD2 improves pregnancy outcomes in systemic lupus erythematosus models. Cell Reports Med 2025;6:102034. https://doi.org/10.1016/j.xcrm.2025.102034. | eng |
| dcterms.references | Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005;2005:CD002859. https://doi.org/10.1002/14651858.CD002859.pub2. | eng |
| dcterms.references | Demir S, Li J, Magder LS, Petri M. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:3770–7. https://doi.org/10.1093/rheumatology/keaa857. | eng |
| dcterms.references | Rout P, Goyal A, Singhal M. Antiphospholipid Syndrome. 2025. | eng |
| dcterms.references | Kotzen ES, Roy S, Jain K. Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus. Adv Chronic Kidney Dis 2019;26:376–86. https://doi.org/10.1053/j.ackd.2019.08.012. | eng |
| dcterms.references | Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”): semantic or antisemantic? Autoimmun Rev 2008;7:164–7. https://doi.org/10.1016/j.autrev.2007.11.009. | eng |
| dcterms.references | Radu A, Dudu SC, Ciobanu A, Peltecu G, Iancu G, Botezatu R, et al. Pregnancy Management in Women with Antiphospholidic Syndrome. Maedica (Buchar) 2019;14:148–60. https://doi.org/10.26574/maedica.2019.14.2.148. | eng |
| dcterms.references | Téllez Noriega JL, Basso V, Fuentes N, Vivero F. Clinical and immunological factors associated with lupus nephritis in an Argentine patient population: A cross-sectional study. Rev Colomb Reumatol (English Ed 2022;29:249–55. https://doi.org/10.1016/j.rcreue.2021.05.003. | eng |
| dcterms.references | Demkova K, Morris DL, Vyse TJ. Genetics of SLE: does this explain susceptibility and severity across racial groups? Rheumatology (Oxford) 2023;62:i15–21. https://doi.org/10.1093/rheumatology/keac695. | eng |
| dcterms.references | Mosca M, Bruce IN, Andersen J, Ugarte-Gil MF, Arnaud L. Challenges and opportunities in access to care for systemic lupus erythematosus patients across Europe and worldwide. Rheumatology (Oxford) 2024;63:1772–8. https://doi.org/10.1093/rheumatology/keae227. | eng |
| dcterms.references | Ugarte-Gil MF, Alarcón GS. Systemic lupus erythematosus in Latin America: Outcomes and therapeutic challenges. Clin Immunol Commun 2023;4:60–4. https://doi.org/10.1016/j.clicom.2023.10.002. | eng |
| dcterms.references | Johnson SR, Urowitz MB, Ibañez D, Gladman DD. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J Rheumatol 2006;33:1990–5. | eng |
| dcterms.references | Ministerio de Salud y Protección Social. Política Nacional para la Prevención y Control de la Enfermedad Renal Crónica. 2022. | spa |
| dcterms.references | Caster DJ, Merchant ML, Klein JB, Powell DW. Precision medicine in lupus nephritis: can biomarkers get us there? Transl Res 2018;201:26–39. https://doi.org/10.1016/j.trsl.2018.08.002. | eng |
| dcterms.references | Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev 2019;18:406–14. https://doi.org/10.1016/j.autrev.2018.12.006. | eng |
| dcterms.references | Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, et al. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis 2018;77:549–55. https://doi.org/10.1136/annrheumdis-2017- 212224. | eng |
| dcterms.references | Cole MA, Gerber GF, Chaturvedi S. Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management. Clin Immunol 2023;257:109828. https://doi.org/10.1016/j.clim.2023.109828. | eng |
| dcterms.references | Erton ZB, Sevim E, de Jesús GR, Cervera R, Ji L, Pengo V, et al. Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (‘Registry’). Lupus Sci Med 2022;9:e000633. https://doi.org/10.1136/lupus2021-000633. | eng |
| dcterms.references | Banos A, Bertsias G. Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention. Curr Rheumatol Rep 2023;25:183–91. https://doi.org/10.1007/s11926-023-01109-6. | eng |
| dcterms.references | Panagiotopoulos A, Kapsia E, Michelakis I, Boletis J, Marinaki S, Sfikakis PP, et al. Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible? RMD Open 2023;9. https://doi.org/10.1136/rmdopen-2023-003158. | eng |
| dcterms.references | Cervera R. [Therapeutic strategies in antiphospholipid syndrome]. Reumatol Clin 2010;6:37–42. https://doi.org/10.1016/j.reuma.2008.11.020. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | |
| sb.programa | Especialización en Medicina Interna | spa |
| sb.sede | Sede Barranquilla | spa |
Archivos
Bloque de licencias
1 - 1 de 1
No hay miniatura disponible
- Nombre:
- license.txt
- Tamaño:
- 2.93 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción: